THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB

被引：1

作者：

Morand, E. ^{[1
]}

Berglind, A. ^{[2
]}

Sheytanova, T. ^{[2
]}

Tummala, R. ^{[2
]}

Illei, G. ^{[3
]}

机构：

[1] Monash Univ, Melbourne, Vic, Australia

[2] AstraZeneca, Molndal, Sweden

[3] MedImmune LLC, Gaithersburg, MD USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.2464

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0001

引用

页码：50 / 50

页数：1

共 50 条

[21] Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus [J].

Oon, Shereen ;

Huq, Molla ;

Golder, Vera ;

Ong, Emily ;

Morand, Eric ;

Nikpour, Mandana .

ARTHRITIS & RHEUMATOLOGY, 2018, 70

[22] Evaluation of the Lupus Low Disease Activity State (LLDAS) vs. the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)-2K Score in a Pediatric Systemic Lupus Erythematosus Cohort [J].

Wilson, Bridget ;

Qiu, Tingting ;

Merritt, Angela ;

Huang, Bin ;

Brunner, Hermine .

ARTHRITIS & RHEUMATOLOGY, 2021, 73 :1570-1573

[23] Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort [J].

Ugarte-Gil, Manuel ;

Ruiz-Irastorza, Guillermo ;

Gladman, Dafna ;

Urowitz, Murray ;

Clarke, Ann ;

Hanly, John ;

Gordon, Caroline ;

Bae, Sang-Cheol ;

Romero-Diaz, Juanita ;

Sanchez-Guerrero, Jorge ;

Bernatsky, Sasha ;

Wallace, Daniel ;

Isenberg, David ;

Rahman, Anisur ;

Merrill, Joan ;

Fortin, Paul R. ;

Bruce, Ian N. ;

Petri, Michelle ;

Ginzler, Ellen ;

Dooley, Mary Anne ;

Ramsey-Goldman, Rosalind ;

Manzi, Susan ;

Jnsen, Andreas ;

van Vollenhoven, Ronald F. ;

Aranow, Cynthia ;

Mackay, Meggan ;

Lim, S. Sam ;

Inanc, Murat ;

Kalunian, Kenneth ;

Jacobsen, Soren ;

Peschken, Christine ;

Kamen, Diane ;

Askanase, Anca ;

Pons-Estel, Bernardo A. ;

Alarcn, Graciela .

ARTHRITIS & RHEUMATOLOGY, 2021, 73 :2639-2641

[24] Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial [J].

Tanaka, Yoshiya ;

Atsumi, Tatsuya ;

Okada, Masato ;

Miyamura, Tomoya ;

Ishii, Tomonori ;

Nishiyama, Susumu ;

Matsumura, Ryutaro ;

Hayashi, Nobuya ;

Matsumoto, Takahiro ;

Yabe-Wada, Toshiki ;

Yamaguchi, Yoshiyuki ;

Abreu, Gabriel ;

Lindholm, Catharina ;

Takeuchi, Tsutomu .

MODERN RHEUMATOLOGY, 2025, 35 (03) :458-469

[25] Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE [J].

Morand, Eric ;

Hobar, Coburn ;

Pomponi, Samantha ;

Koti, Ravi ;

Wegman, Thomas ;

van Vollenhoven, Ronald .

ARTHRITIS & RHEUMATOLOGY, 2023, 75 :2961-2963

[26] LLDAS (LOW LUPUS DISEASE ACTIVITY STATE), LOW DISEASE ACTIVITY (LDA) AND REMISSION (ON- OR OFF-TREATMENT) PREVENT DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS IN A MULTINATIONAL MULTICENTER COHORT [J].

Ugarte-Gil, M. F. ;

Hanly, J. ;

Urowitz, M. B. ;

Gordon, C. ;

Bae, S. C. ;

Romero-Diaz, J. ;

Sanchez-Guerrero, J. ;

Bernatsky, S. ;

Clarke, A. E. ;

Wallace, D. J. ;

Isenberg, D. ;

Rahman, A. ;

Merrill, J. T. ;

Fortin, P. ;

Gladman, D. D. ;

Bruce, I. N. ;

Petri, M. A. ;

Ginzler, E. M. ;

Dooley, M. A. ;

Ramsey-Goldman, R. ;

Manzi, S. ;

Jonsen, A. ;

Van Vollenhoven, R. ;

Aranow, C. ;

Mackay, M. ;

Ruiz-Irastorza, G. ;

Lim, S. S. ;

Inanc, M. ;

Kalunian, K. C. ;

Jacobsen, S. ;

Peschken, C. ;

Kamen, D. L. ;

Askanase, A. ;

Pons-Estel, B. ;

Alarcon, G. S. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 :177-178

[27] Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus [J].

Morand, Eric F. ;

Franklyn, Kate ;

Lau, Chak S. ;

Navarra, Sandra V. ;

Louthrenoo, Worawit ;

Lateef, Aisha ;

Hamijoyo, Laniyati ;

Wahono, Singgih ;

Chen, Shun-Le ;

Ou, Jinou ;

Hoi, Alberta Y. ;

Nikpour, Mandana .

ARTHRITIS AND RHEUMATISM, 2013, 65 :S664-S665

[28] BASELINE FACTORS ASSOCIATED WITH LUPUS FLARES: A POST-HOC ANALYSIS OF PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS ENROLLED IN A 48 WEEK PHASE II RANDOMIZED CLINICAL TRIAL [J].

Lindsay, L. ;

Mao, H. A. ;

Cheng, J. E. ;

Chuo, C. Y. ;

Jones, N. ;

Cascino, M. D. ;

Tuckwell, K. .

ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 :648-648

[29] SLE-DAS enables an accurate definition of severe lupus disease activity: derivation and validation in a post hoc study of anifrolumab phase II and III studies [J].

Jesus, Diogo ;

Matos, Ana ;

Henriques, Carla ;

Doria, Andrea ;

Ines, Luis Sousa .

LUPUS SCIENCE & MEDICINE, 2025, 12 (01)

[30] Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients [J].

Zheng, Bo ;

Yu, Xiang-Qing ;

Greth, Warren ;

Robbie, Gabriel J. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (05) :918-928

← 1 2 3 4 5 →